LXEO (Lexeo Therapeutics) EBIT: $-87.32 Mil (TTM As of Mar. 2026)

What is Lexeo Therapeutics EBIT?

Lexeo Therapeutics LXEO -3.69% 10 EBIT is $-87.32 Mil as of Mar. 2026. GuruFocus rates LXEO with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

Lexeo Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-20.18 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-87.32 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Lexeo Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -127.07%. Lexeo Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -938.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Lexeo Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -47.62%.

Lexeo Therapeutics (NAS:LXEO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lexeo Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-89.332 * ( 1 - 0% )	/	( (87.11	+	53.489)	/ 2 )
=	-89.332	/	70.2995
=	-127.07 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	268.688	-	9.994	-	( 181.767	-	max(0, 16.808	-	188.392	+	181.767	))
=	87.11

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	250.356	-	10.194	-	( 193.043	-	max(0, 14.189	-	200.862	+	193.043	))
=	53.489

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Lexeo Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-80.716	/	( ( (8.857 + max(-7.508, 0))	+	(8.346 + max(-3.675, 0)) )	/	2 )
=	-80.716	/	( ( 8.857	+	8.346 )	/	2 )
=	-80.716	/	8.6015
=	-938.39 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	6.625)	-	(9.994	+	0	+	4.139)
=	-7.508

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	7.819)	-	(10.194	+	0	+	1.3)
=	-3.675

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lexeo Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-87.318	/	183.378
	=	-47.62 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexeo Therapeutics EBIT Related Terms

Lexeo Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Lexeo Therapeutics's EBIT can be seen below:

Lexeo Therapeutics EBIT Chart

Lexeo Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-50.62

-59.19

-66.19

-98.20

-99.76

Lexeo Therapeutics Quarterly Data
	Dec20	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial													-32.62	-26.04	-20.20	-20.89	-20.18

LXEO vs LYEL, XFOR, ZURA: EBIT Comparison

For the Biotechnology subindustry, Lexeo Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lexeo Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lexeo Therapeutics's EV-to-EBIT falls into.

Save Embed

10GF Score

Lexeo Therapeutics Inc LXEO

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Lexeo Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-87.32 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-87.32 Mil mean?

Lexeo Therapeutics (LXEO) has a EBIT of $-87.32 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lexeo Therapeutics.

Is Lexeo Therapeutics' EBIT too high?

Lexeo Therapeutics' current EBIT is $-87.32 Mil. Overall, Lexeo Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does Lexeo Therapeutics' EBIT compare to LYEL and XFOR?

Lexeo Therapeutics' EBIT of $-87.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lexeo Therapeutics. Lexeo Therapeutics's current EBIT is $-87.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Lexeo Therapeutics stock overvalued right now?

Lexeo Therapeutics (LXEO) has a current EBIT of $-87.32 Mil. The current EBIT is $-87.32 Mil. Lexeo Therapeutics' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Lexeo Therapeutics (LXEO), the current EBIT is $-87.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lexeo Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies LYEL XFOR ZURA BNTC OABI CYDY FBRX VNDA ARTV ENTA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 345 Park Avenue South, Floor 6, New York, NY, USA, 10010

Website https://www.lexeotx.com

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

10GF Score

Get the complete analysis for LXEO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.70

Price

View LXEO Analysis

See EBIT data for all stocks →